Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Talking about a successful merger

How communications can support effective mergers and acquisitions outcomes

ApotheCom ScopeMedical expands team

ApotheCom ScopeMedical names new members of its senior management team

- PMLiVE

ASCO: Amgen says viral therapy for melanoma “encouraging”

T-VEC is potential advancement in skin cancer treatment

- PMLiVE

GSK’s Tyverb/ Tykerb disappoints in gastric cancer trial

Fails to improve overall survival in proposed new indication

EU flag

Nine pharma firms face EU fines over pay-for-delay deals

Lundbeck could be the hardest hit with a maximum penalty of €240m

- PMLiVE

AstraZeneca drops arthritis candidate fostamatinib

Hands rights back to Rigel after late-stage trial disappointment

- PMLiVE

Lilly’s Strattera wins new adult ADHD licence in UK

On course for wider EU approval for adults yet to receive treatment

- PMLiVE

Kite Pharma appoints Zelboraf scientist as CMO

Keith Nolop joins US cancer biotech from Plexxikon

- PMLiVE

EMA backs Pomalidomide Celgene in multiple myeloma

Further positive CHMP opinions for new medicines form Aegerion, Teva and more

- PMLiVE

ASCO: Merck and BMS trumpet melanoma trials

Positive study results for anti-PD-1 candidates lambrolizumab and nivolumab

Sanofi reception

Sanofi gives up on iniparib and otamixaban

Drops cancer drug and anticoagulant after negative late-stage trials

- PMLiVE

GSK/ Valeant’s Trobalt set for EU restrictions

Eye concerns prompt CHMP to recommend last-line use for the epilepsy drug

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links